NTx has re-imagined how biomanufacturing can be done, using a proprietary, easily scalable, continuous flow, cell-free system that fits on a benchtop or in a small isolator glovebox, with the goal of democratizing the production of RNA and proteins, to enable global access to the next generation of vaccines and therapeutics.Using our proprietary enzymes and bioreactor systems, we can make RNA (including mRNA, saRNA, etc.) in a fraction of the time and cost, simultaneously decreasing purification and other associated costs using traditional bioprocessing methods. The technology systems are also efficiently tunable, making them useful to address product updates that may be needed (e.g. to address new virus variants, like in COVID). The technology enables R&D and clinical production of next-generation therapeutic modalities, like self-amplifying RNA, which are incredibly difficult to manufacture using commercially available equipment and processes.

Sema4 is a health information company founded on the idea that more information, deeper analysis, and increased engagement will improve the diagnosis, treatment, and prevention of disease. A Mount Sinai Health System venture based in Stamford, Conn., Sema4 is enabling physicians and consumers to more seamlessly engage the digital universe of data, from genome test results and clinical records to wearable sensor metrics and more. The company currently offers advanced genome-based diagnostics for reproductive health and oncology and is building predictive models of complex disease. Sema4 believes that patients should be treated as partners, and that data should be shared for the benefit of all. Grew company from sub 50m to over 200m in revenue in 4 years. Grew staff from 300 to over 1000 people. Successful $3.8B IPO in 2021 and subsequently merged with GENEDX. Raised over 800M in capital.

Took over as CEO and Chairman of Source Medical in December 2014, a private equity owned company. It was the leading provider of software and revenue cycle solutions in the Ambulatory Surgical space and physical therapy space. Led all aspects of corporate operations and business development. Acquired LaClaro in May 2015. Successful sale/spin off of the Therapy division in Nov 2016. Built an industry leading partner ecosystem and forged a partner footprint in the industry second to none. Turned Source into the recognized thought leader and market share leader for the ASC space. Successfully exited the surgery division in May 2017 with sale to Surgical Information Systems.

Member of the the board of directors of this small VC funded high performance computing software company focused on applications in the life sciences and academic computing fields. Had been responsible for helping CEO drive new business and partnerships in my short tenure there through my contacts in the healthcare and life sciences industry. Sold company to Cray Inc.

Led a world-class team to build an innovative model in genomic medicine by rolling up US pathology and genomic IP assets. Pitched to over 15 PE firms to fund the $300M required to implement the rollup. . Team consisted of some of the leading experts in the pathology and genomics field. The unsettled pathology reimbursement environment prevented a successful completion of this initiative..

Full P&L responsibility for Global HCLS business. Over 6 year period, grew organization to 13000 WW. Transformed this business from a hardware only (mostly PCs) business into the #1 HC IT services company in the world. Changed perception of Dell in this industry to the leading solutions provider in the HC industry. Shifted the mix in the business to over a 55% Services business, with massive increase in profitability.• Led successful transformation of the healthcare group in Dell. Integrated all accounts across Dell into a cross functional unit, including Payer, Provider, Pharma, Biotech, Devices and Diagnostics, and all ISVs. Built highly experienced HCLS team and transformed Dell team into an integrated solutions sales team. Massive recruiting effort of over 3000 industry experts, including over 50 Ph.Ds. and over 400 clinicians. Moved Dell from a minor player in the HCLS industry into the leading HC IT services company in the world.• Made Dell the leading HCLS Cloud Provider globally. Led the acquisition and integration of two major companies into Dell Led the integration of the HC team from Perot Systems into Dell . In 2010, acquired and integrated a leading HC imaging VNA/Archive team called Insite One. Signed large agreements to become the cloud provider for Siemens, AGFA, and Merge Healthcare, making our Unified Clinical Archive solution the de facto standard for cloud-based medical archiving.• Architected and led Dell’s signature giving program called Powering the Possible for Pediatric Cancer. Program is a $30M program to develop new cures for pediatric neuroblastoma, using next generation genomics and high performance computing. Built global pediatric cancer network in the cooperation with the Translational Genomics Center. Developed innovative cloud computing platform as part of the first clinical trial in personalized medicine for pediatric cancer.

The Alliance was created in 2005 as a 501(c)(3) non-profit organization with a mission to support the NIH Oxford-Cambridge Scholars Program and associated global Ph.D. and M.D./Ph.D. training programs based in the Intramural Research Program of the National Institutes of Health, America’s largest biomedical research organization. Its goal is to assure the financial viability and scientific excellence of the Scholars’ program by supplementing government funding. The Alliance supports program events and scholarships designed to enrich the program and broaden the perspectives of its highly selective students as they train to become the next leaders in biomedical research.

Challenged to merge an unfocused healthcare and thriving life science industry business as part of a sales growth initiative. Core activities include leading a $5 billion server, software, and service business with global leadership of 800+ sales, new business development, and technical support professionals. Preside over P&L management, business strategies, WW sales leadership, new business development, global partner ecosystem management, multi-million dollar sales negotiations, and high performance computing sales leadership. Spearhead the development of a new emerging business in information-based medicine, valued at $400 million. • Led successful turnaround for a troubled healthcare industry business that had lost 10 points market share for the last four years. In 18 months, healthcare rapidly became the fastest growth industry in IBM and delivered 20% growth year-over-year. Achieved 24% growth in 2004 and 22% growth in 2005.• Success was delivered by realigning sales coverage and sales talent, targeting high growth customers and markets, establishing C-level business relationships across the US, and reengineering IBM’s strategies.

Tapped for global leadership role based on rich technical acumen, research background, life sciences sales success, and vast experience in the highly technical life science industry. Also selected based on an extensive life science industry network, an ability to recruit industry experts, and build credibility in the life science industry.Commissioned to establish a new WW Life Science Division, hire and lead sales, consulting, business development, and technical support teams, spearhead global sales, create global sales strategies, design a sales pipeline, cultivate customer relationships, build a global business partner network, oversee brand management, create new solutions for life science customers, and participate in sales transactions. Led teams charged with selling technology products to pharmaceutical, biotech, bioinformatics, instrument, education, and government markets. Assembled a team that worked with venture capital firms and helped them drive technology into their portfolio companies. Collaborated with VC executives to create business plans, go-to-market strategies, and recruit talent. Moreover, designed investment strategies as IBM invested in small informatics companies. • Driving force behind success of newly formed Life Science Division. Pushed annual sales of servers, software, and professional services from $30 million in 2000 to $2+ billion in 2004, and grew team from six to 1,000+ in four years. Surpassed annual goals by as much as 220% of plan.• Personally, led a team which won IBM’s prestigious Lou Gerstner Award (2001) for outstanding accomplishments in building a new Life Science Division and landing a major deal with Celera Corporation. First division to ever win this top corporate award. Recognized as the “Most Outstanding Team” due to explosive growth.• Division was applauded for leading the most successful growth initiative in IBM’s history. Accomplishment paved the way for a new initiative in Information Based Medicine.

Accepted challenge to architect a sales strategy in the academic research space which moved ranking from 9th place to 1st place in the supercomputing industry. Principal activities involved academic technical computing sales, creating relationships with research leaders, forming C-level relationships with elite research universities, driving academic collaboration, igniting market share and sales in the supercomputing industry, and positioning IBM as an innovative thought leader in the industry.Focused on directing team that sold high-end RS6000 and servers across North America, hiring and training sales force in high-end technical computing, training software vendors and business partners, preparing multi-million dollar bids, designing marketing strategies, and more.• Captured #1 market share in the high performance computing industry; major accomplishment helped drive several competitors to bankruptcy.• Teamed with a sales professional to secure $92 million in high end hardware and software products in 1999.• Managed IBM’s Grant Programs in the academic industry and leveraged grant programs to work with elite academic institutions. Catalyst in positioning IBM as a “go to” company in the life sciences scientific space.• Positioned IBM as an industry expert in molecular biology, computational chemistry, and physical chemistry.• Served on the Colorado School of Mines Advisory Board, and consulted with professionals working on a Quantum Theory Project at the University of Florida.• Involved in IBM’s Post Doc Program and recruited top-level students. • Conducted sales presentations to 400+ universities across North America in three years.